SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalum

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.

Related Keywords

Boston , Massachusetts , United States , Dana Farber Cancer Institute , Bristol Myers Squibb , Roche Genentech , Calithera Biosciences , Tonik Choueiri , Platformq Health , Pharma Group , Pfizer , Glaxosmithkline , Corvus Pharmaceuticals , Life Sciences , Kidney Cancer Association , Alexion Pharmaceuticals , Analysis Group , Serono , Database Consortium , Gilead Sciences , Navinata Health , Astrazeneca , Sanofi Aventis , Health Interactions , Fishawack Group Of Companies , Infinity Pharmaceuticals , Novartis , Kidney Cancer Research Summit , Alkermes , Foundation Medicine , International Metastatic , Precede Bio , Tempest Therapeutics , Arcus Biosciences , Clinical Care Options , Harborside Press , Janssen Oncology , Kanaph Therapeutics , Lancet Oncology , Nikang Therapeutics , Peloton Therapeutics , Scholar Rock , New England Journal , Clinical Response , Immune Checkpoint Inhibitor Therapy , Anti Immune Checkpoint Response , Cerulean Pharma , Envision Pharma Group , Fishawack Group , Cancer Research Summit , Leej L , D , Harvard Medical School , Usameta , Savolitinib Plus Durvalumab , Met Driven Papillary Rcc , Renal Cell Carcinoma , Ct05043090 ,